Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc.

The Descartes Systems Group ( ($TSE:DSG) ) has provided an update. Descartes Systems Group has introduced AI-powered Image Document Management capa...

Descartes Launches Embedded AI Document Management to Speed Customs and Shipping

RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics on August 3 and set a price target of $20.00. The company’s shar...

RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)

Cantor Fitzgerald analyst maintained a Buy rating on Design Therapeutics today and set a price target of $40.54. In a report released yesterday, Cr...

Cantor Fitzgerald Remains a Buy on Design Therapeutics (DSGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Design Therapeutics (DSGN), Certara (CERT) and Gen...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DSGN	$15.52	+1.64%	317.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DSGN	$15.52	+1.6%	317.53K
3
4
5
6

DSGN

Get Design Therapeutics, Inc. Data in Excel

Get Design Therapeutics, Inc. Data in Excel